In the phase 2 FAKTION trial, we showed that the addition of capivasertib to fulvestrant endocrine therapy resulted in a significant improvement of progression-free survival in postmenopausal women with aromatase inhibitor-resistant ER-positive, HER2-negative advanced breast cancer.17 This evidence concerns the gene ERBB2 and breast carcinoma.